Author + information
- Received November 5, 2013
- Revision received January 22, 2014
- Accepted January 23, 2014
- Published online March 1, 2014.
- Victor A. Ferrari, MD∗∗ (, )
- Brian Whitman†,
- James C. Blankenship, MD‡,
- Matthew J. Budoff, MD§,
- Marco Costa, MD‖,
- Neil J. Weissman, MD¶,
- Manuel D. Cerqueira, MD#,
- ACC Imaging Council
- ∗Department of Medicine (Cardiovascular Medicine) and Penn Cardiovascular Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
- †American College of Cardiology, Washington, DC
- ‡Department of Cardiology, Geisinger Medical Center, Danville, Pennsylvania
- §David Geffen School of Medicine at University of California–Los Angeles, Los Angeles, California
- ‖Division of Cardiology, University Hospitals Case Medical Center, Case Western Reserve School of Medicine, Cleveland, Ohio
- ¶MedStar Health Research Institute and Georgetown University, Washington, DC
- #Imaging and Heart and Vascular Institutes, Cleveland Clinic and Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio
- ↵∗Reprint requests and correspondence:
Dr. Victor A. Ferrari, 9010 E. Gates Pavilion/HUP, 3400 Spruce Street, Philadelphia, Pennsylvania 19104.
Uncertainty regarding the future of cardiovascular (CV) services and reimbursement systems in this era of rapid change in health care delivery may lead to further confusion among imagers. This article provides a brief history of national payment and reimbursement systems, and discusses potential changes that will impact CV imaging in the coming years. Data over the last decade are presented on payment and utilization of services to demonstrate the impact of reimbursement reforms and education on imaging use.
Dr. Ferrari is an Executive Committee member of the Society for Cardiovascular Magnetic Resonance. Dr. Blankenship is a member of the Relative Value Scale Update Committee (RUC), Chair of the ACC RUC Task Force, and on the Executive Committee of the Society for Cardiac Angiography and Interventions. Dr. Costa has served as an Officer, Director, Trustee, or other Fiduciary Role for StemMed and Genae; has received consultant fees or honoraria from Edwards LifeSciences, Medtronic, Abbott Vascular, Boston Scientific, Cardiokinetix, St. Jude Medical, and NIH-CCTRN; holds ownership interest/partnership/principal from genae Americas, and StemMed Inc.; and has served as a committee member for the Society of Cardiac Angiography and Interventions. Dr. Cerqueira is a consultant for FluoroPharma, Astellas, and GE Healthcare and is on the Speakers’ Bureau of Astellas. Dr. Budoff is a consultant for GE Healthcare. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The first 2 authors contributed equally to this work.
- Received November 5, 2013.
- Revision received January 22, 2014.
- Accepted January 23, 2014.